Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 February 2024 | Story André Damons | Photo SUPPLIED
Prof Robert Bragg
Prof Robert Bragg is a researcher in the Department of Microbiology and Biochemistry at the University of the Free State (UFS) and believes hospital-acquired infections (HAIs) might already be “Disease X”.

During the World Governments Summit, the World Health Organisation (WHO) warned world leaders about the likelihood of a Disease X outbreak, saying it is “a matter of when, not if” a new pathogen and pandemic will strike. If there is an outbreak of this disease tomorrow, the world still would not be ready. 

During his speech earlier this month at the summit in Dubai, Tedros Adhanom Ghebreyesus, Director-General of the WHO, said COVID-19 was a Disease X – a new pathogen causing a new disease. He said: “There will be another Disease X, or a Disease Y or a Disease Z. And as things stand, the world remains unprepared for the next Disease X, and the next pandemic. If it struck tomorrow, we would face many of the same problems we faced with COVID-19.”

Though Disease X is a hypothetical placeholder representing yet-to-be-encountered pathogens, Prof Robert Bragg, researcher in the Department of Microbiology and Biochemistry at the University of the Free State (UFS), believes hospital-acquired infections (HAI) might already be “Disease X”. He says data shows that deaths from HAIs will become the leading cause of human deaths. This problem is rapidly growing as most of the pathogens which people contract while in hospital are now resistant to antibiotics, making them very difficult to treat.  

Prof Bragg, whose main research is in disease-control, first in the agricultural industry, and now human health, also previously warned about a disease that would make COVID-19, which killed more than seven million people to date globally, look like a dress rehearsal. His PhD student, Samantha Mc Carlie, investigating how bacteria become resistant to disinfectant and sanitiser products. This is a serious problem for the future, as disinfection could be our last line of defence.

Heading for a crisis in health care

“The world is rapidly heading for a crisis in health care regarding hospital-acquired infections. It is common knowledge that we are quickly running out of antibiotics (and antifungals) to treat bacterial and yeast infections. Without antibiotics and antifungals, the outcome of many of these bacterial and yeast hospital-acquired infections will be very severe. They will, unfortunately, in many cases, result in the death of the patient,” says Prof Bragg. 

According to him, the WHO suggests that 30% of patients in ICUs in developed countries and 70% in underdeveloped countries will contract a HAI. Of these, the mortality rate can be as high as 70%. 

“Most of these infections are caused by multiple drug resistance strains of bacteria such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species. Additional bacteria and yeast, which can also cause HAIs, such as Serratia species, are also becoming a concern due to their intrinsic higher levels of disinfectant resistance.”

Prof Bragg explains that in 2014, a high-profile review was first published, commissioned by the UK Prime Minister, entitled, “Antimicrobial Resistance: Tackling a crisis for the Health and Wealth of Nations” (the AMR Review). This review estimated that antimicrobial resistance (AMR) could cause 10 million deaths annually by 2050 (The Review on Antimicrobial Resistance 2016). This is the same number of deaths caused by cancer today, making AMR the leading cause of human mortality by 2050. When it was finalised, this report was highly criticised as an over-dramatisation, as when this prediction was made, the number of mortalities related to HAIs was around 700 000 – a very long way off 10 000 000. However, according to recent estimates, five years later, in 2019, 1.27 million deaths were directly attributed to drug-resistant infections globally, and this had reached 4.95 million deaths associated with bacterial AMR (including those directly attributable to AMR) by 2022 (Murray et al. 2022). 

The overuse of disinfectants during the COVID-19 pandemic, according to Prof Bragg and Mc Calie, has contributed to the crisis by fostering resistant strains and contaminating environments. Based on the current trajectory of mortalities, the 10 million mark will be reached way before 2050.

Need for a paradigm shift

The researchers say an urgent need to change the paradigm in medicine from “treatment” to “prevention” is necessary and that the old saying ‘prevention is better than cure’ has never been truer. 

According to Bragg: “The golden era of antibiotics is rapidly coming to an end. It is highly unlikely that we will discover new antibiotics, and even if we do, the likelihood that the bacteria will already have or will be able to develop resistance in a very short time is highly likely. 

“We need to think of what happed with quinolones, where we thought we had won the war with a groundbreaking new antimicrobial agent. The bacteria did not have millions of years of evolution to develop resistance to quinolone, yet in only three years, the first resistant bacteria were isolated. There is currently great excitement around AI-derived new antibiotics. However, the end result is likely to be the same. We need an alternative to treatment – in other words, a paradigm shift.” 

Improved biosecurity 

Prof Bragg says highly improved biosecurity is the only viable option for disease control in a post-antibiotic era. By using good biosecurity in poultry production, he says the mortality rates were reduced by 50%. 

Research has shown a direct link between the environmental microbial load in a hospital and HAIs; with a lower microbial load linked to lower incidence of HAIs including C. difficile infections (Boyce et al. 2008; Suleyman et al. 2018; Umemura et al., 2022). Therefore, the new paradigm is to reduce microbial contamination in the hospital environment to prevent HAIs. If there are fewer dangerous microorganisms in an environment, patient and staff exposure to these microorganisms will decrease, reducing the level of HAIs for staff and patients. However, to reduce the microbial loads in healthcare settings, effective cleaning and disinfection products need to be used. 

News Archive

School of Medicine – heartbeat of the UFS
2015-06-24

Photo: Charl Devenish

During the past year, the School of Medicine at the University of the Free State celebrated several successes in the field of research and cooperation agreements. These successes allow the school to continue delivering world-class teaching to some of the country’s top students.

Earlier this year, a research team from the Department of Medical Microbiology under the guidance of Prof Felicity Burt, received a grant of R500 000 to conduct research on Congo fever (CCHF). Prof Burt is an internationally-recognised expert on Congo fever. The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. This study may contribute to the development of a vaccine against this deadly virus.

Prof Stephen Brown from the Department of Paediatrics and Child Health’s expertise and commitment to paediatric cardiology gained him the title of Bloemfonteiner of the Year. Under the leadership of Prof Brown, the department has performed many breakthrough operations and procedures. The most recent of these, was the first hybrid procedure in the country which was performed in November 2014. The department also has an ultramodern hybrid heart catheterisation suite.
 
Prof William Rae from the Department of Medical Physics focuses on medically-applied radiation. Together with his department, they are looking at quantitative radiation dosages. The research is particularly crucial for the successful treatment of cancers. Through this research, it is possible to ensure that patients receive the appropriate radiation dosages in order to obtain the desired effect without the patient being affected negatively.

Dr Nathanial Mofolo, Head of the Department of Family Medicine in the School of Medicine, is since 2006 involved at various levels of hospital management regarding quality assurance, patient safety, clinical and infection management, as well as administration. He is currently curator of internal medical students for four of the UFS’s teaching hospitals. His department is currently focusing on the National Health Plan, HIV and tuberculosis, teaching and learning, as well as service delivery in family medicine.
 
Prof Francis Smit manages the team that, to their knowledge, decellularised the first primate heart. The method has been applied successfully on rat and pig hearts by researchers in America. Recently the team also successfully cultivated beating heart cells ? those of a rat ? in their laboratories. The research is in line with what researchers in Europe and America are working on. In the long run, the research project aims to attempt ‘building’ a heart that could be used for the purposes of organ donation.

The UFS is also home to the only metabolic research unit in the country. The unit was established to focus research on obesity, type II diabetes, metabolic bone diseases and all related diseases. This includes diseases such as diabetes, cholesterol, cancer, psoriasis, lymphoedema, fatigue, high blood pressure, gout, arthritis, fibrosis, skin disorders, PMT, migraine, insomnia, gall and kidney stones and related infections, and obstructive sleep apnea. The unit is a joint initiative between the UFS and Christo Strydom Nutrition. Mr Christo Strydom, a nutritionist and world renowned in the treatment of lymphoedema, invested R5 million in the establishment of this unit at the UFS.  Christo Strydom is also the founder and owner of Christo Strydom Nutrition.

The School of Medicine at the University of the Free State is the only unit on the continent offering in-depth modules in clinical simulation. The Clinical Simulation Unit on the Bloemfontein Campus of the UFS, headed by Dr Mathys Labuschagne, is regarded as the flagship unit of the school and boasts high-technology equipment where students can practice their clinical skills before applying those skills in the real world.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept